If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
But you only post on Aukett, there has to be more to it....please let me know how I can get in ouch with you
You are virtually the only poster here and make intelligent observation but are not invested...why is that, you don’t post anywhere else? Want to get involved in an ntervention?
I have the impression that you may be ex-insider and/or have a significant exposure to Aukett.is the correct?
Can you pm me bear17?
Elartu, the technology of AI in cancer monitoring and machine reading of images is moving so fast that it is not surprising that shareholders and (if I may venture an opinion) even the Feedback board of part timers, could not keep up to date with developments...what was once state of the art can quickly becomes a quaint relationship in sch an environment
https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0195270&type=printable
https://mint-medical.com/products-solutions/
Please can someone help me with this - surely textural analysis software is not available elsewhere?
Adrianz, it is clear that their ambition exceeds "speed up MRI times". The real problem is open sourcing and the consequences of having unlimited resources available to crack any problems. Textural Analysis is no more immune from innovation and alternative applications of AI than any other field.
"In the interest of advancing the state of the art in medical imaging as quickly as possible, ***we plan to open-source this work*** to allow the wider research community to build on our developments. As the project progresses, Facebook will share the AI models, baselines, and evaluation metrics associated with this research, and NYU School of Medicine will open-source the image data set. This will help ensure the work’s reproducibility and accelerate adoption of resulting methods in clinical practice"
https://code.fb.com/ai-research/facebook-and-nyu-school-of-medicine-launch-research-collaboration-to-improve-mri/
Complacency kills
Have we considered what has happened in the (now vast) imaging analysis sector since Feedback was re-listed in 2014. It is a shame that there is never any discussion here about the potential and actual competition. Logically it would be surprising to find that that the thousands of other researchers in medical image analysis have made no significant progress over the last four plus years. There are now a large number of business and projects in the medical imaging texture and AI arena - take a few moments to google
Isn't it worrying that even after four years only the research version of the software is being sold, since there must be a natural limit in how many research projects based on texture analysis can be supported, even globally? Is the GE deal actually a sale to GE, or is it the TexRad research software which researchers have been buying for the last four years loaded as an optional extra on a GE scanner at the buyers request, ie the scanner doesn't come loaded with it as OE. There seems little sign of commercial sales, what would the product be - is there one? Research software is not a commercial medical product surely? listen carefully to Alastair's podcast (but see below also)
There has been some comment here on Mike Hayball's share sales. Mike was very closely involved in the development of TexRad software and until, very recently was a main board director of Feedback....now he has left the main plc board, as has David Crabb who departed abruptly after a few months as CEO. So Trevor Brown, Tom Chalrton, Balaji Ganashan, Mike Hayball, and David Crabb have all gone leaving part-time Alastair and a couple of non-execs plus a finance director to run things.
In all these circumstances it is sobering to replay Alastair's podcast from November 2016
https://www.youtube.com/watch?v=Air0tAMHvec
Shaz, Elartu and b others, if anything was going on there could have been no dealing by insiders, eg Mike H. For clarity, the TexRad software has only ever been sold fr research purposes and there seems no prospect of commercial sales because apart from anything else, there is NO PRODUCT,
There aren’t any products. Even the GE deal is software for research purposes. My guess is that without the steadying and cost controlling hand of Mr Crabb, costs are likely to increase without any benefit to the sharp end. After two full years of Alastair at the helm, albeit part time, the main products seem to be board changes and a couple of funding rounds....
Selling....has caused little comment here. Following on so closely from the abrupt departure of David Crabb and with MH potentially having more to sell doesn’t inspire. With Trev long gone, Is MH or DC to be the next scapegoat ? Presumably if MH is cleared to sell, there is no news in the pipeline? I’m sure one of the regulars here can put a positive spin on this but I’m left scratching my head....
Conventional imaging takes multiple months (minimum of 3, potentially 6 months) to assess if the treatment therapy is working � due to pseudoprogression (edema, steroid effects) that often mimics TRUE progression on conventional imaging � especially with new anti-angiogenic agents. Studies suggest that fractional tumour burden (FTB) can assess if a patient is responding much sooner (e.g. 2 weeks). If you think about the life expectancy with brain tumour patients, that difference (a few weeks vs. 4-6 months) cannot be understated.